J
Jeannette M. Dowell
Researcher at Duke University
Publications - 23
Citations - 4194
Jeannette M. Dowell is an academic researcher from Duke University. The author has contributed to research in topics: Glioma & Cancer. The author has an hindex of 20, co-authored 23 publications receiving 4068 citations. Previous affiliations of Jeannette M. Dowell include Durham University & University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
James J. Vredenburgh,Annick Desjardins,James E. Herndon,Jeannette M. Dowell,David A. Reardon,Jennifer A. Quinn,Jeremy N. Rich,Sith Sathornsumetee,Sridharan Gururangan,Melissa Wagner,Darell D. Bigner,Allan H. Friedman,Henry S. Friedman +12 more
TL;DR: The combination of bevacizumab and irinotecan is an active regimen for recurrent grade III-IV glioma with acceptable toxicity and no central nervous system hemorrhages occurred.
Journal ArticleDOI
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Jeremy N. Rich,David A. Reardon,Terry S. Peery,Jeannette M. Dowell,Jennifer A. Quinn,Kara Penne,Carol J. Wikstrand,Lauren B. Van Duyn,Janet Dancey,Roger E. McLendon,James C. Kao,Timothy T. Stenzel,B.K. Ahmed Rasheed,Sandra Tourt-Uhlig,James E. Herndon,James J. Vredenburgh,John H. Sampson,Allan H. Friedman,Darell D. Bigner,Henry S. Friedman +19 more
TL;DR: Gefitinib is well tolerated and has activity in patients with recurrent glioblastoma and further study of this agent at higher doses is warranted.
Journal ArticleDOI
Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme
David A. Reardon,Merrill J. Egorin,Jennifer A. Quinn,Jeremy N. Rich,Idharan Gururangan,James J. Vredenburgh,Annick Desjardins,Sith Sathornsumetee,James M. Provenzale,James E. Herndon,Jeannette M. Dowell,Michael A. Badruddoja,Roger E. McLendon,Theodore F. Lagattuta,Kimberly P. Kicielinski,Gregor Paul Dresemann,John H. Sampson,Allan H. Friedman,A. Salvado,Henry S. Friedman +19 more
TL;DR: Imatinib mesylate plus hydroxyurea is well tolerated and associated with durable antitumor activity in some patients with recurrent glioblastoma multiforme (GBM).
Journal ArticleDOI
Frequent Inactivation of PTEN by Promoter Hypermethylation in Microsatellite Instability-High Sporadic Colorectal Cancers
Ajay Goel,Christian N. Arnold,Christian N. Arnold,Donna Niedzwiecki,John M. Carethers,John M. Carethers,Jeannette M. Dowell,Linda Wasserman,Carolyn C. Compton,Robert J. Mayer,Monica M. Bertagnolli,C. Richard Boland,C. Richard Boland,C. Richard Boland +13 more
TL;DR: The first demonstration of PTEN inactivation as a result of promoter hypermethylation in MSI-H sporadic CRCs is demonstrated, suggesting that PTEN is an additional important "target" of methylation along with the hMLH1 gene in the evolution of MSI- H CRCs and also confers the "second hit" in the biallelic inactivation mechanism for some proportion of tumors.
Journal Article
Characterization of Sporadic Colon Cancer by Patterns of Genomic Instability
Ajay Goel,Christian N. Arnold,Donna Niedzwiecki,Dong K. Chang,Luigi Ricciardiello,John M. Carethers,Jeannette M. Dowell,Linda Wasserman,Carolyn C. Compton,Robert J. Mayer,Monica M. Bertagnolli,C. Richard Boland,C. Richard Boland,C. Richard Boland +13 more
TL;DR: The data suggest that molecular mechanisms of genomic instability are not necessarily independent and may not be fully defined by either the MSI or CIN pathways.